{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:28Z","timestamp":1786998448877,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ygyno.2022.12.009","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T21:41:00Z","timestamp":1671745260000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study"],"prefix":"10.1016","volume":"169","author":[{"given":"Sarah","family":"Ehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William A.","family":"Zammarrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effi","family":"Yeoushoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.12.009_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.12.009_bb0010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5662\/wjm.v5.i4.196","article-title":"Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients","volume":"5","author":"Minig","year":"2015","journal-title":"World J. Methodol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.009_bb0015","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ygyno.2022.12.009_bb0020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.12.009_bb0025","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2022.12.009_bb0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2022.12.009_bb0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.12.009_bb0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.12.009_bb0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.12.009_bb0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","article-title":"Maximal cytoreductive effort in epithelial ovarian cancer surgery","volume":"21","author":"Shih","year":"2010","journal-title":"J. Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.009_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2022.12.009_bb0060","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ygyno.2022.12.009_bb0065","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2022.12.009_bb0070","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ygyno.2022.12.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA 1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.009_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2021.07.030","article-title":"Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy","volume":"163","author":"Basaran","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2022.12.009_bb0085","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/ijgc-2020-001641","article-title":"Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study","volume":"30","author":"Liu","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"suppl_8","key":"10.1016\/j.ygyno.2022.12.009_bb0090","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.12.009_bb0095","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajog.2019.06.009","article-title":"Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer","volume":"221","author":"Gockley","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"23","key":"10.1016\/j.ygyno.2022.12.009_bb0100","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2022.12.009_bb0105","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.ygyno.2022.12.009_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2021.05.015","article-title":"Tertiary cytoreduction for recurrent ovarian carcinoma: an updated and expanded analysis","volume":"162","author":"Manning-Geist","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.12.009_bb0115","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","article-title":"Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation","volume":"20","author":"Fotopoulou","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2022.12.009_bb0120","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.12.009_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.12.009_bb0130","first-page":"2821","article-title":"Efficacy of dexamethasone in the management of malignant small bowel obstruction in advanced epithelial ovarian cancer","volume":"30","author":"Jones","year":"2022","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2022.12.009_bb0135","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/IGC.0000000000001049","article-title":"Malignant bowel obstruction in relapsed ovarian Cancer with peritoneal Carcinomatosis: an occlusive state","volume":"27","author":"Martinez Castro","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2022.12.009_bb0140","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1634\/theoncologist.11-3-252","article-title":"Brain metastases from epithelial ovarian cancer: a review of the literature","volume":"11","author":"Pectasides","year":"2006","journal-title":"Oncologist."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.009_bb0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.009_bb0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ygyno.2019.05.004","article-title":"Brain metastasis in epithelial ovarian cancer by BRCA 1\/2 mutation status","volume":"154","author":"Stasenko","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.12.009_bb0155","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.009_bb0160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ygyno.2012.12.016","article-title":"Global ovarian cancer health disparities","volume":"129","author":"Chornokur","year":"2013","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822019965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822019965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:03:51Z","timestamp":1758773031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822019965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":32,"alternative-id":["S0090825822019965"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}